2021•Tropical Medicine and Infectious DiseaseOpen access
Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali
Modibo Diarra, Drissa Moriba Coulibaly, Amadou Tapily, Bouréima Guindo, Koualy Sanogo, Diakalia Koné, Youssouf Koné, Karim Koné, Aboudramane Bathily, Oumar Yattara, Mahamadou Ali Thera, Alassane Dicko, ABDOULAYE A. DJIMDÉ, Issaka Sagara
Open full text 1 citations
Abstract
In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization’s standard 28-day treatment method. The primary endpoint was the clinical and parasitological response corrected by a polymerase chain reaction. It was more than 99.9 percent, the proportion of patients with anemia significantly decrease compared to baseline (p < 0.001), and no serious events were recorded. Plasmodium falciparum remains sensitive to artemether-lumefantrine in Mali.
Open-access reader